



Differentiation Between Early and Severe Stages of Dementia in Claims Data Based on Diagnosis, Prescription, and Utilization Patterns

Moritz Platen · Maresa Buchholz · Anika Rädke · Eva Gläser · Audrey Iskandar ·
Neeltje van den Berg · Wolfgang Hoffmann · Bernhard Michalowsky

Received: April 16, 2025 / Accepted: May 14, 2025 / Published online: June 12, 2025
© The Author(s) 2025

ABSTRACT

Introduction: Claims data typically lack clinical parameters such as dementia severity, limiting insights into disease progression and related healthcare utilization and costs. Although diagnoses, prescriptions, and utilization patterns may serve as proxies, their validity is unclear. This study aimed to identify and validate these parameters to distinguish early from severe dementia stages.

Methods: Baseline data from 737 patients with dementia were analyzed. Dementia severity was assessed using the Mini-Mental State Examination and classified as early (≥ 27), mild (20–26), and moderate to severe (0–19). Healthcare utilization was recorded via structured interviews.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40120-025-00778-y>.

M. Platen (✉) · M. Buchholz · A. Rädke · E. Gläser ·
A. Iskandar · W. Hoffmann · B. Michalowsky
German Center for Neurodegenerative Diseases
(DZNE), Site Greifswald, Ellernholzstrasse 1-2,
17489 Greifswald, Germany
e-mail: moritz.platen@dzne.de

N. van den Berg · W. Hoffmann
Section Epidemiology of Health Care
and Community Health, Institute for Community
Medicine, University Medicine Greifswald (UMG),
Ellernholzstrasse 1-2, 17489 Greifswald, Germany

Diagnoses, long-term care levels, and prescribed medications were extracted from physicians' files. Ordinal logistic regression evaluated associations between predictors and severity, with average marginal effects (AME) quantifying impact. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed for key predictors.

Results: Among the sample (56% female patients, mean age 80), 18% were in the early stages, 43% mild, and 39% moderate to severe. Antipsychotic prescriptions (odds ratio (OR) 3.40, 95% confidence interval (CI) 1.94–5.95), antidementia drugs (OR 2.31, 95% CI 1.56–3.40), and higher long-term care levels (OR 5.59, 95% CI 2.23–13.99 for level ≥ 4) were associated with advanced severity. AME analysis revealed that antipsychotic use reduced early-stage probability by 14% and increased severe-stage probability by 21%. Similarly, antidementia drugs lowered early-stage probability by 9% and raised severe-stage probability by 13%. Increasing care levels were associated with a 2–16% decline in early-stage probability and a 3–34% rise in severe-stage probability. The combined model showed high specificity (99.6%) and PPV (84.6%) for severe dementia, but sensitivity and NPV for early stage were low.

Conclusion: Antidementia drugs, antipsychotics, and long-term care level serve as robust predictors of moderate to severe dementia, whereas early-stage detection remains challenging.

Future studies should validate these markers and explore additional predictors to improve early detection in claims data.

Keywords: Alzheimer's disease; Antidementia drug treatment; Antipsychotics; Claims data; Dementia; Dementia severity; Healthcare utilization; Real-world data; Real-world evidence

Key Summary Points

Why carry out this study?

Real-world data, like claims data, typically lack clinical parameters such as dementia severity, reducing their utility in healthcare decision-making for evaluating the cost-effectiveness of innovative therapies, e.g., disease-modifying drugs for Alzheimer's disease.

This study aimed to identify and validate predictors (documented diagnoses, prescriptions, healthcare utilization patterns) commonly available in German claims records to differentiate early-stage from moderate-to-severe dementia.

What was learned from the study?

The analysis revealed that antipsychotic use, guideline-based antidementia drug prescriptions, and higher long-term care levels are strongly associated with moderate-to-severe dementia, achieving high specificity and positive predictive value.

Despite the strong performance for advanced dementia, the model demonstrated lower sensitivity in detecting early-stage dementia, indicating that many early cases may remain unclassified.

These findings underscore the potential of integrating routine claims data for dementia severity classification while highlighting the need for additional markers and refined algorithms to enhance early detection and guide efficient resource allocation.

INTRODUCTION

Routinely collected real-world data from health insurers complement evidence from randomized controlled trials and are becoming increasingly important, particularly for regulatory decision-making [1–4]. Although administrative claims data has proven valuable in identifying disease cases using diagnostic codes, a critical limitation is the lack of clinical parameters that enable a more detailed look into the disease severity. This limitation reduces the utility of claims data in understanding healthcare service utilization costs in the progression of different diseases in vulnerable populations, such as dementia.

This is especially important if interventions aim to start as early as possible and claims data could be used to reveal the impact of such interventions in different disease stages. Without the prospect of a cure, dementia care needs to ensure the best possible individualized treatment and care as early as possible to delay the progression of cognitive decline, increase or maintain health-related quality of life, and enable individuals to live as long as possible in the community. Hence, the therapeutic goal is to relieve the burden on patients, caregivers, and the healthcare system [5]. Several disease-modifying drug treatments that target dementia at onset or even before symptoms occur, such as lecanemab or donanemab, are currently in development or already recommended for approval by responsible regulatory authorities [6, 7].

However, successfully implementing these treatments and care strategies requires a precise understanding of the affected populations and their needs at different stages of dementia [8–10]. Therefore, to ensure the efficient allocation of limited resources and to assess the cost-effectiveness of innovative therapies, it is essential to identify the target population, analyze their healthcare utilization patterns, and evaluate the impact of dementia severity on health economic outcomes. Currently, this is not possible on the basis of claims data because of the missing information on disease severity, and so far, no claims-based algorithm to measure dementia severity exists [11–13].

Recent studies have addressed this gap by developing models using proxy measures (e.g., claims-based frailty index) or machine learning approaches to estimate dementia severity [14–17]. However, these approaches are often accompanied by a lack of generalizability due to a focus on specific healthcare settings and are confounded by undercoding or underdiagnosing of early-stage dementia [18–20]. Healthcare utilization and prescription patterns can indirectly indicate disease severity and treatment adjustments over time [21, 22]. However, the low treatment rates of people living with dementia (PwD) with antidementia drugs pose an additional challenge [23, 24]. A more precise and comprehensive classification of dementia severity in claims data may be achieved by integrating broader prescribing patterns, e.g., antipsychotic use alongside diagnostic codes and documented prodromal features, risk factors, and comorbidities [17, 25, 26]. However, so far, such approaches have not been systematically validated.

Given these challenges and opportunities, this primary data-based study aims to (1) identify predictors of dementia severity using documented diagnoses according to the 10th edition of the International Classification of Diseases and Related Health Problems (ICD-10), prescription, and healthcare utilization patterns commonly available in German claims records and (2) validate their ability to distinguish early from advanced dementia stages to provide novel insights into the potential of real-world data for assessing dementia severity and supporting regulatory and clinical decision-making.

METHODS

Study Design and Recruitment

This cross-sectional analysis utilized merged baseline data from three independent trials: DelpHi-MV (ClinicalTrials.gov identifier NCT01401582), InDePendent (ClinicalTrials.gov identifier NCT04741932), and DCM:IMPact (German Clinical Trials Register Reference No. DRKS00025074). These trials' detailed designs

and methodologies have been published previously [27–29].

In total, 1218 community-dwelling PwD had been recruited through general practitioner (GP) practices, physician networks, or daycare centers by qualified study nurses. Participants were eligible for inclusion if they met the following criteria: a DemTect [30] score < 9 or a listed clinical dementia diagnosis, age ≥ 70 years, and residing at home. Written informed consent had been obtained from all participants, and the trials were approved by the Ethical Committee of the Chamber of Physicians of Mecklenburg-Western Pomerania (registry numbers BB 20/11 for DelpHi-MV, BB01/2019 for DCM:IMPact, and BB144/20 for InDePendent). This has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Seven hundred thirty-seven participants (61%) with complete baseline data on cognitive impairment, diagnoses, prescriptions and healthcare utilization were considered for the current analysis.

Data Assessment

Sociodemographic and Clinical Characteristics

Study nurses conducted comprehensive, standardized, computer-assisted face-to-face interviews at the participants' homes, in which the following variables were assessed: age, sex, cognitive impairment according to the Mini-Mental State Examination (MMSE) [31], and the care level assigned by the long-term care insurance for the amount of care and support a patient receives owing to their functional impairment in daily activities—not the underlying disease severity [27–29]. The care level ranges from 1 to 5, with 1 indicating some problems and 5 indicating extreme problems and determining entitlement to formal care services or financial reimbursement for informal caregiving. In addition, the diagnoses according to the ICD-10 classification and prescribed medication listed in the medical record of the treating physician were collected.

Dementia Severity

Cognitive impairment was assessed using the MMSE and categorized into four severity groups based on the national S3 dementia guideline, representing the highest methodological quality for evidence-based recommendations: no indication of dementia ($\text{MMSE} \geq 27$), mild dementia ($\text{MMSE } 20\text{--}26$), moderate dementia ($\text{MMSE } 10\text{--}19$), and severe dementia ($\text{MMSE} \leq 9$) [32]. Additionally, patients without a listed clinical dementia diagnosis were screened using the DemTect procedure, whereby a score < 9 indicates dementia. The DemTect is considered more sensitive and suitable for detecting early stages of dementia compared to the MMSE [33]. Consequently, participants with an $\text{MMSE} \geq 27$ and $\text{DemTect} < 9$ were classified as having early-stage dementia due to the initial screening result. As a result of the small group size, patients with moderate or severe dementia were combined into one group for the analyses.

Healthcare Utilization

Healthcare resource use was also assessed within the baseline interviews using the standardized FIMA questionnaire tailored to elderly individuals considering the specifications and all settings in the German healthcare system [34]. Detailed information about the frequencies of the utilization of the following medical care services was recorded: physician consultation (GP, specialists), therapies (e.g., occupational, physical, and speech therapy), and hospital contacts. Prescribed medications were extracted from medication lists provided by the treating physicians. To improve the validity and precision of the data, study nurses interviewed caregivers, participants, and professional care staff wherever possible.

Selection of Pattern to Differentiate Dementia Severity Stages

Pre- and post-diagnostic factors were included to cover all stages of dementia severity and mitigate potential selection bias. Pre-diagnostic patterns to identify the early stages were chosen on the basis of Teipel et al. [35], which comprised diagnostic

codes for comorbidities, risk, and prodromal factors. Patterns reflecting the post-diagnostic treatment and care of more severe stages were mainly derived from the most recent German S-3 dementia guideline [32]. Finally, the potential factors to differentiate dementia severity stages were checked for availability in both the claims data and the used dataset. Variables with fewer than ten observations were excluded to ensure explanatory power and heterogeneity.

Statistical Analyses

The sociodemographic and clinical characteristics of study participants and health resource utilization were presented using descriptive statistics. One-way analysis of variance (ANOVA) (continuous variables) and chi-square tests (categorical variable, > 2 conditions) were employed to assess group differences across dementia severity stages. Ordered logistic regression models, adjusting for age, sex, and the respective original trial, were used to explore associations between predictors and dementia severity, with odds ratios (ORs) reported. Average marginal effects (AME) were calculated to estimate how predictors influenced the probabilities of specific severity stages. The Bonferroni correction was applied to correct for multiple comparisons ($\alpha_{\text{corrected}} = 0.001$).

Additionally, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed for selected statistically significant predictors, individually and in combination, to assess their ability to differentiate and exclude overlapping severity stages. Depending on the direction of the observed associations, it was assumed that sensitivity and PPV might increase while specificity and NPV might decrease with increasing severity or vice versa.

All statistical analyses were conducted with STATA/IC software, version 18 [36].

RESULTS

Sample Characteristics

The 737 participants (mean age 80.3 years; 56% female patients) were categorized into

early-stage (18%), mild (43%), and moderate/severe dementia (39%), according to the MMSE. Patients with early-stage dementia were significantly younger (early-stage 79 years vs. mild 80 years vs. moderate/severe 81 years; $p=0.032$) and less likely to have a listed clinical dementia diagnosis (38.9% vs. 22.2% vs. 16.8%; $p\leq 0.001$, respectively). Table 1 summarizes the sample characteristics.

Associations Between Diagnosis and Treatment Patterns and Dementia Severity

After the Bonferroni correction was applied, ordinal logistic regression analysis revealed the following statistically significant associations: antipsychotic use (OR 3.40, 95% confidence interval (CI) 1.94–5.95, $p\leq 0.001$) and antidementia drug prescriptions according to guidelines (OR 2.31, 95% CI 1.56–3.40, $p\leq 0.001$) were strong predictors of moderate to severe dementia. Additionally, care levels demonstrated a stepwise relationship with increasing dementia severity, from care level 2 (OR 2.04, 95% CI 1.33–3.12, $p\leq 0.001$) to care level 4 or higher (OR 5.59, 95% CI 2.23–13.99, $p\leq 0.001$). Conversely, fewer medications (OR 0.90, 95% CI 0.86–0.95, $p\leq 0.001$) were associated with milder dementia stages. Other variables, including unspecified and specified dementia diagnoses, cancer, and therapies, were no longer significant after Bonferroni correction. Table 2 shows the results of the ordinal logistic regression analysis. Additionally, Supplementary Table 1 reports the unadjusted frequencies and group differences of comorbidities and healthcare utilization between different stages.

The AME analysis revealed that antipsychotic prescriptions decreased the probability of being classified as early-stage dementia according to the MMSE by 14% while increasing the probability of being classified as having moderate/severe dementia by 21%. Similarly, antidementia drug treatments reduced the probability of early-stage dementia classification by 10% and increased the probability of moderate/severe dementia by 14%. Depending on the care level, probabilities of early-stage classification decrease by 2–16%, and moderate/severe classification probabilities

increase by 3–33%. Other factors, including age, sex, comorbidities, and health service utilization, did not significantly predict the classification of dementia severity. Table 3 presents the AME for the respective severity stages.

Performance Metrics for Dementia Severity Classification: Sensitivity, Specificity, NPV, and PPV

The analysis revealed clear patterns of predictors (antidementia drugs, antipsychotics, and care level) to discriminate dementia severity. For antidementia drugs, sensitivity increased from 15.3% in early-stage dementia to 34.3% in moderate-to-severe dementia, and specificity rose from 72.0% to 79.6%. NPV was highest in the early stage (79.7%) but decreased to 65.6% in the severe stages. PPV showed a notable rise from 10.5% to 51.6%, indicating a stronger association with severe dementia. For antipsychotics, sensitivity was lowest in the early stages (3.8%) but increased to 17.8% in severe cases, while specificity improved from 87.3% to 93.1%. Early-stage NPV was high (80.8%) but declined to 64.1% for severe stages. PPV showed a marked improvement from 6.1% to 62.2%, emphasizing its utility in identifying severe dementia. For care level, sensitivity rose substantially from 11.5% in the early stages to 40.2% in severe dementia, with a slight increase in specificity from 70.6% to 82.7%. NPV declined from 78.7% to 68.6%, while PPV increased significantly from 7.8% to 59.6%, underscoring its strength as a predictor of severe dementia. All predictors combined achieved the highest specificity of up to 99.6% and PPV of up to 84.6% for moderate-to-severe dementia, demonstrating excellent discriminatory power. Table 4 summarizes diagnostic performance.

DISCUSSION

This study provides novel insights into the potential of routinely collected real-world data for classifying dementia severity on the basis of diagnostic codes, prescribing patterns, and healthcare utilization. Our findings suggest

Table 1 Sample characteristics

	Total sample		Early-stage dementia MMSE ≥ 27		Mild dementia MMSE 20–26		Moderate to severe dementia MMSE 0–19		<i>p</i> value
	<i>n</i> = 737	95% CI	<i>n</i> = 131 (17.8%)	95% CI	<i>n</i> = 320 (43.4%)	95% CI	<i>n</i> = 286 (38.8%)	95% CI	
Demographics									
Age, mean (SD)	80.3 (5.9)	79.8–80.7	79.1 (5.7)	78.2–80.1	80.3 (5.2)	79.7–80.8	80.8 (6.5)	80.0–81.5	0.032 ^b
Sex (female patients), <i>n</i> (%)	413 (56.0)	0.52–0.59	64 (48.8)	0.40–0.57	185 (57.8)	0.52–0.63	164 (57.3)	0.51–0.62	0.187 ^c
Clinical characteristics									
Listed clinical dementia diagnosis, <i>n</i> (%)									
No diagnosis, <i>n</i> (%)	170 (23.0)	0.20–0.26	51 (38.9)	0.30–0.47	71 (22.19)	0.17–0.27	48 (16.7)	0.12–0.21	$\leq 0.001^c$
Unspecified dementia diagnosis, <i>n</i> (%)	328 (44.5)	0.40–0.48	51 (38.9)	0.30–0.47	142 (44.38)	0.39–0.49	135 (47.20)	0.39–0.49	
Specified dementia diagnosis, <i>n</i> (%)	239 (32.4)	0.29–0.35	29 (22.14)	0.15–0.30	107 (33.44)	0.28–0.38	103 (36.01)	0.30–0.41	
Alzheimer's disease, <i>n</i> (%)	110 (14.9)	0.12–0.17	11 (8.40)	0.04–0.14	47 (14.69)	0.11–0.19	52 (18.18)	0.14–0.23	0.033 ^c
Other dementia disease, <i>n</i> (%)	129 (17.5)	0.14–0.20	18 (13.74)	0.08–0.20	60 (18.75)	0.14–0.23	51 (17.83)	0.13–0.22	0.438 ^c
Number of diagnoses, mean (SD)	12.3 (8.2)	11.7–12.8	13.1 (7.8)	11.7–14.4	12.7 (7.5)	11.9–13.5	11.4 (9.0)	10.3–12.4	0.070 ^b
Number of medications, mean (SD)	7.5 (3.7)	7.2–7.8	7.9 (3.2)	7.4–8.5	7.7 (4.0)	7.3–8.2	7.1 (3.4)	6.7–7.5	0.034 ^b

Table 1 continued

	Total sample		Early-stage dementia MMSE ≥ 27		Mild dementia MMSE 20–26		Moderate to severe dementia MMSE 0–19		<i>p</i> value
	<i>n</i> = 737	95% CI	<i>n</i> = 131 (17.8%)	95% CI	<i>n</i> = 320 (43.4%)	95% CI	<i>n</i> = 286 (38.8%)	95% CI	
Care level ^a									
No care level, <i>n</i> (%)	281 (38.1)	0.34–0.41	75 (57.2)	0.48–0.65	157 (49.0)	0.43–0.54	49 (17.1)	0.13–0.21	≤ 0.001^c
1, <i>n</i> (%)	38 (5.1)	0.03–0.07	5 (3.8)	0.01–0.08	13 (4.0)	0.02–0.06	20 (6.9)	0.04–0.10	
2, <i>n</i> (%)	225 (30.5)	0.27–0.33	36 (27.4)	0.20–0.35	87 (27.1)	0.22–0.32	102 (35.6)	0.30–0.41	
3, <i>n</i> (%)	142 (19.2)	0.16–0.22	13 (9.9)	0.05–0.16	54 (16.8)	0.13–0.21	75 (26.2)	0.21–0.31	
4 or higher, <i>n</i> (%)	51 (6.9)	0.05–0.08	2 (1.5)	0.01–0.05	9 (2.8)	0.01–0.05	40 (13.9)	0.10–0.18	

p values in bold indicate *p* < 0.05
CI confidence interval, *MMSE* Mini-Mental State Examination (range 0–30, higher score indicates better cognitive function), *SD* standard deviation
^aThe care level assigned by the long-term care insurance indicates the amount of care and support a patient receives owing to their functional impairment, ranging from 1 to 5, with 1 indicating some problems and 5 indicating extreme problems
^bDifferences in means: one-way ANOVA
^cDifferences in proportions: chi-square tests

that the combination of antidementia drug prescriptions, antipsychotic use, and assigned care levels serves as a strong predictor of moderate to severe dementia, demonstrating high specificity and PPV. Conversely, early-stage dementia classification showed lower sensitivity, highlighting challenges in identifying individuals at an earlier disease stage on the basis of real-world data.

The predictive performance of our model varied across dementia severity stages. For moderate to severe dementia, specificity and PPV were particularly high when combining antidementia drugs, antipsychotic use, and care level (specificity 99.6%, PPV 84.6%). This indicates that these variables reliably identify individuals with severe dementia and produce few misclassifications among those with less severe dementia, making them valuable markers for classifying dementia severity in claims data. Additionally, the increase in PPV across stages, particularly for antipsychotic use (from 6.1% in early-stage to 62.2% in severe dementia), aligns with clinical

practice, where these medications are more frequently prescribed with behavioral and psychological symptoms progress [37–39]. This is also underlined by the AME analysis, demonstrating antipsychotic prescriptions reduced early-stage probability by 14% and increased severe-stage classification by 21%, reinforcing their strong association with advanced disease.

Consistently, early-stage dementia classification showed lower sensitivity and PPV, particularly for antidementia drug use (sensitivity 15.3%, PPV 10.5%). This suggests that many individuals in the early stages could remain undetected, possibly because of a lack of dementia-specific pharmacological treatment, which could be considered as a result of underdiagnosis. The AME analysis further supports this, showing that antidementia drug treatment reduced the probability of being classified as early-stage dementia by 9% while increasing the probability of moderate to severe dementia classification by 14%. Previous studies indicated that only 39% of people who screened positive

Table 2 Associations between diagnosis and treatment patterns and dementia severity

<i>N</i> = 737	Severity stages of dementia according to MMSE ^a			
	OR	SE	95% CI	<i>p</i> value
Demographics				
Age ^c	1.01	0.01	0.98–1.04	0.349
Sex (ref. male) ^c	1.14	0.19	0.81–1.60	0.424
Clinical characteristics				
Number of diagnoses ^c	0.99	0.01	0.96–1.02	0.619
Listed clinical dementia diagnosis ^c				
Unspecified dementia (ref. no diagnosis)	1.72	0.35	1.16–2.57	0.007
Specified dementia (ref. no diagnosis)	1.75	0.39	1.11–2.73	0.014
Comorbidities ^d				
Abnormalities of gait (ref. no diagnosis)	0.82	0.22	0.48–1.41	0.495
Tremor (ref. no diagnosis)	1.87	1.17	0.54–6.41	0.318
Extremity injury (ref. no diagnosis)	0.84	0.40	0.32–2.17	0.719
Anxiety (ref. no diagnosis)	0.83	0.51	0.24–2.81	0.768
Cognitive impairment (ref. no diagnosis)	1.34	0.97	0.32–5.53	0.679
Depression (ref. no diagnosis)	1.16	0.26	0.74–1.81	0.515
Memory impairment (ref. no diagnosis)	0.66	0.21	0.34–1.26	0.213
Visual impairment (ref. no diagnosis)	1.04	0.47	0.43–2.53	0.924
Hearing impairment (ref. no diagnosis)	0.81	0.20	0.50–1.33	0.422
Other sensory disorders (ref. no diagnosis)	0.66	0.79	0.06–6.99	0.734
Insomnia (ref. no diagnosis)	0.81	0.51	0.23–2.78	0.734
Other sleeping disorder (ref. no diagnosis)	1.02	0.57	0.34–3.07	0.964
Sleep apnea (ref. no diagnosis)	0.41	0.24	0.12–1.34	0.143
Constipation (ref. no diagnosis)	0.52	0.30	0.16–1.61	0.261
Dizziness (ref. no diagnosis)	0.75	0.22	0.42–1.34	0.347
Obesity (ref. no diagnosis)	1.43	0.38	0.84–2.42	0.178
Alcohol abuse (ref. no diagnosis)	0.72	0.41	0.23–2.25	0.573
Nicotine abuse (ref. no diagnosis)	0.66	0.45	0.17–2.54	0.557
Atrial fibrillation (ref. no diagnosis)	0.72	0.15	0.47–1.08	0.121
Carotid artery stenosis (ref. no diagnosis)	0.71	0.27	0.33–1.51	0.385
Cerebrovascular disease (ref. no diagnosis)	0.92	0.18	0.62–1.37	0.709
Type 2 diabetes mellitus (ref. no diagnosis)	1.09	0.18	0.78–1.53	0.588
Hypercholesterolemia (ref. no diagnosis)	0.71	0.19	0.41–1.22	0.217
Hypertension (ref. no diagnosis)	1.14	0.21	0.78–1.66	0.477
Ischemic heart disease (ref. no diagnosis)	1.36	0.24	0.96–1.94	0.083

Table 2 continued

<i>N</i> = 737	Severity stages of dementia according to MMSE ^a			
	OR	SE	95% CI	<i>p</i> value
Gastritis (ref. no diagnosis)	1.49	0.43	0.84–2.64	0.172
Reflux disease (ref. no diagnosis)	0.73	0.19	0.43–1.24	0.253
Stomach ulcer (ref. no diagnosis)	1.95	1.25	0.55–6.91	0.297
Epilepsy (ref. no diagnosis)	4.71	2.70	1.53–14.50	0.007
Parkinsons disease (ref. no diagnosis)	1.31	0.50	0.61–2.78	0.477
Cancer (ref. no diagnosis)	1.61	0.36	1.03–2.50	0.034
Osteoarthritis (ref. no diagnosis)	0.95	0.17	0.66–1.37	0.823
Other rheumatoid arthritis (ref. no diagnosis)	0.76	0.38	0.28–2.05	0.594
Senility (ref. no diagnosis)	1.72	0.60	0.86–3.42	0.121
Unspecific pain (ref. no diagnosis)	0.97	0.26	0.57–1.64	0.930
Healthcare utilization				
Number of medications ^d	0.90	0.02	0.86–0.95	≤ 0.001
PIM (ref. no use) ^d	0.87	0.19	0.56–1.33	0.533
Antipsychotics (ref. no use) ^c	3.40	0.97	1.94–5.95	≤ 0.001
Sedative and hypnotics (ref. no use) ^c	1.14	0.46	0.51–2.55	0.742
Antidepressants (ref. no use) ^c	1.17	0.27	0.74–1.87	0.484
Antidementia drug treatment (ref. no use) ^c	2.31	0.45	1.56–3.40	≤ 0.001
Number GP contacts ^d	0.99	0.01	0.97–1.02	0.744
Specialist contacts (ref. no use) ^c	0.72	0.13	0.49–1.05	0.095
Number hospital contacts ^c	0.99	0.01	0.97–1.00	0.373
Therapies contacts (ref. no use) ^c	0.69	0.11	0.50–0.96	0.031
Nursing contacts (ref. no use) ^c	0.89	0.16	0.61–1.29	0.541
Care level ^{b,c}				
1 (ref. no assignment)	1.22	0.51	0.54–2.77	0.620
2 (ref. no assignment)	2.04	0.44	1.33–3.12	≤ 0.001
3 (ref. no assignment)	2.19	0.62	1.25–3.82	0.006
4 or higher (ref. no assignment)	5.59	2.61	2.23–13.99	≤ 0.001

p values in bold indicate $p \leq 0.001$

CI confidence interval, GP general practitioner, *MMSE* Mini-Mental State Examination (range 0–30, higher score indicates better cognitive function), *OR* odds ratio, *PIM* potentially inappropriate medication, *SE* standard error

^aOrdinal scaled variable with 1 indicating early-stage, 2 mild, and 3 moderate to severe dementia

^bThe care level assigned by the long-term care insurance indicates the amount of care and support a patient receives owing to their functional impairment, ranging from 1 to 5, with 1 indicating some problems and 5 indicating extreme problems

^cAssumption based on literature: factor/variable is associated with higher severity

^dAssumption based on literature: factor/variable is associated with lower severity

Table 3 Average marginal effects of diagnosis and treatment patterns on dementia severity stages

<i>N</i> = 737	Early-stage dementia (17.8%)			Mild dementia (43.4%)			Moderate to severe dementia (38.8%)		
	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value
Demographics									
Age ^b	± 0.00	– 0.01 to 0.01	0.349	± 0.00	– 0.01 to 0.01	0.350	± 0.00	– 0.00 to 0.01	0.348
Sex (ref. male) ^b	– 0.01	– 0.05 to 0.02	0.424	– 0.01	– 0.02 to 0.01	0.426	0.02	– 0.03 to 0.08	0.423
Clinical characteristics									
Number of diagnoses ^b	± 0.00	– 0.01 to 0.01	0.619	± 0.00	– 0.01 to 0.01	0.619	± 0.00	– 0.01 to 0.01	0.619
Listed clinical dementia diagnosis ^b									
Unspecified dementia (ref. no diagnosis)	– 0.07	– 0.12 to 0.01	0.010	– 0.02	– 0.04 to 0.01	0.007	0.09	0.02 to 0.16	0.006
Specified dementia (ref. no diagnosis)	– 0.07	– 0.13 to 0.01	0.016	– 0.02	– 0.04 to 0.01	0.026	0.09	0.02 to 0.17	0.014
Comorbidities ^c									
Abnormalities of gait (ref. no diagnosis)	0.02	– 0.04 to 0.08	0.495	0.01	– 0.02 to 0.04	0.498	– 0.03	– 0.12 to 0.06	0.495
Tremor (ref. no diagnosis)	– 0.07	– 0.22 to 0.07	0.318	– 0.03	– 0.10 to 0.03	0.317	0.11	– 0.10 to 0.33	0.316
Extremity injury (ref. no diagnosis)	0.02	– 0.09 to 0.13	0.719	0.01	– 0.04 to 0.06	0.719	– 0.03	– 0.20 to 0.13	0.719
Anxiety (ref. no diagnosis)	0.02	– 0.12 to 0.17	0.768	0.01	– 0.05 to 0.07	0.768	– 0.03	– 0.24 to 0.18	0.768
Cognitive impairment (ref. no diagnosis)	– 0.03	– 0.20 to 0.13	0.679	– 0.01	– 0.09 to 0.06	0.679	0.05	– 0.19 to 0.30	0.679
Depression (ref. no diagnosis)	– 0.01	– 0.07 to 0.03	0.515	– 0.01	– 0.03 to 0.01	0.514	0.02	– 0.05 to 0.10	0.514
Memory impairment (ref. no diagnosis)	0.05	– 0.02 to 0.12	0.212	0.02	– 0.01 to 0.06	0.221	– 0.07	– 0.18 to 0.04	0.212

Table 3 continued

<i>N</i> = 737	Early-stage dementia (17.8%)			Mild dementia (43.4%)			Moderate to severe dementia (38.8%)		
	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value
Visual impairment (ref. no diagnosis)	− 0.01	− 0.11 to 0.10	0.924	± 0.00	− 0.05 to 0.04	0.924	0.01	− 0.15 to 0.16	0.924
Hearing impairment (ref. no diagnosis)	0.02	− 0.03 to 0.08	0.421	0.01	− 0.01 to 0.03	0.424	− 0.03	− 0.12 to 0.05	0.421
Other sensory disorders (ref. no diagnosis)	0.04	− 0.23 to 0.33	0.734	± 0.00	− 0.11 to 0.15	0.734	− 0.07	− 0.49 to 0.34	0.734
Insomnia (ref. no diagnosis)	0.02	− 0.12 to 0.17	0.734	0.01	− 0.05 to 0.08	0.734	− 0.03	− 0.25 to 0.18	0.734
Other sleeping disorder (ref. no diagnosis)	± 0.00	− 0.13 to 0.13	0.964	± 0.00	− 0.06 to 0.06	0.964	± 0.00	− 0.19 to 0.20	0.964
Sleep apnea (ref. no diagnosis)	0.10	− 0.03 to 0.24	0.143	0.04	− 0.01 to 0.11	0.150	− 0.15	− 0.36 to 0.05	0.142
Constipation (ref. no diagnosis)	0.07	− 0.05 to 0.21	0.261	0.03	− 0.02 to 0.10	0.268	− 0.11	− 0.31 to 0.08	0.261
Dizziness (ref. no diagnosis)	0.03	− 0.03 to 0.10	0.347	0.01	− 0.01 to 0.04	0.348	− 0.04	− 0.15 to 0.05	0.346
Obesity (ref. no diagnosis)	− 0.04	− 0.10 to 0.01	0.178	− 0.02	− 0.05 to 0.01	0.184	0.06	− 0.02 to 0.15	0.177
Alcohol abuse (ref. no diagnosis)	0.03	− 0.09 to 0.17	0.573	0.01	− 0.04 to 0.08	0.573	− 0.05	− 0.26 to 0.14	0.573
Nicotine abuse (ref. no diagnosis)	0.04	− 0.11 to 0.21	0.557	0.02	− 0.05 to 0.09	0.557	− 0.07	− 0.30 to 0.16	0.556
Atrial fibrillation (ref. no diagnosis)	0.03	− 0.01 to 0.08	0.121	0.01	− 0.01 to 0.04	0.126	− 0.05	− 0.13 to 0.01	0.119

Table 3 continued

<i>N</i> = 737	Early-stage dementia (17.8%)			Mild dementia (43.4%)			Moderate to severe dementia (38.8%)		
	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value
Carotid artery stenosis (ref. no diagnosis)	0.04	− 0.05 to 0.13	0.385	0.01	− 0.02 to 0.06	0.388	− 0.05	− 0.19 to 0.07	0.384
Cerebrovascular disease (ref. no diagnosis)	0.01	− 0.03 to 0.05	0.710	± 0.00	− 0.01 to 0.02	0.709	− 0.01	− 0.08 to 0.05	0.709
Type 2 diabetes mellitus (ref. no diagnosis)	− 0.01	− 0.05 to 0.02	0.588	− 0.01	− 0.02 to 0.01	0.589	0.01	− 0.04 to 0.07	0.588
Hypercholesterolemia (ref. no diagnosis)	0.04	− 0.02 to 0.10	0.217	0.01	− 0.01 to 0.04	0.219	− 0.06	− 0.15 to 0.03	0.215
Hypertension (ref. no diagnosis)	− 0.01	− 0.06 to 0.02	0.477	− 0.01	− 0.02 to 0.01	0.480	0.02	− 0.04 to 0.09	0.477
Ischemic heart disease (ref. no diagnosis)	− 0.03	− 0.08 to 0.01	0.082	− 0.01	− 0.03 to 0.01	0.089	0.05	− 0.01 to 0.11	0.081
Gastritis (ref. no diagnosis)	− 0.04	− 0.11 to 0.02	0.171	− 0.02	− 0.05 to 0.01	0.178	0.07	− 0.03 to 0.17	0.171
Reflux disease (ref. no diagnosis)	0.03	− 0.02 to 0.10	0.254	0.01	− 0.01 to 0.04	0.256	− 0.05	− 0.14 to 0.03	0.252
Stomach ulcer (ref. no diagnosis)	− 0.08	− 0.23 to 0.07	0.298	− 0.03	− 0.10 to 0.03	0.301	0.11	− 0.10 to 0.34	0.297
Epilepsy (ref. no diagnosis)	− 0.18	− 0.32 to − 0.05	0.007	− 0.08	− 0.15 to − 0.02	0.009	0.27	0.07 to 0.47	0.006
Parkinsons disease (ref. no diagnosis)	− 0.03	− 0.12 to 0.05	0.477	− 0.01	− 0.05 to 0.02	0.479	0.04	− 0.08 to 0.18	0.477
Cancer (ref. no diagnosis)	− 0.05	− 0.11 to − 0.01	0.034	− 0.02	− 0.05 to − 0.01	0.040	0.08	0.01 to 0.16	0.033
Osteoarthritis (ref. no diagnosis)	± 0.00	− 0.03 to 0.04	0.823	± 0.00	− 0.01 to 0.02	0.823	− 0.01	− 0.07 to 0.05	0.823

Table 3 continued

<i>N</i> = 737	Early-stage dementia (17.8%)			Mild dementia (43.4%)			Moderate to severe dementia (38.8%)		
	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value
Other rheumatoid arthritis (ref. no diagnosis)	0.03	− 0.08 to 0.15	0.594	0.01	− 0.04 to 0.07	0.595	− 0.04	− 0.22 to 0.12	0.594
Senility (ref. no diagnosis)	− 0.06	− 0.14 to 0.01	0.121	− 0.03	− 0.07 to 0.01	0.129	0.09	− 0.02 to 0.21	0.120
Unspecific pain (ref. no diagnosis)	± 0.00	− 0.06 to 0.06	0.930	± 0.00	− 0.02 to 0.03	0.930	± 0.00	− 0.09 to 0.08	0.930
Healthcare utilization									
Number of medications ^b	0.01	0.01 to 0.01	≤ 0.001	0.01	0.002 to 0.01	≤ 0.001	− 0.01	− 0.02 to − 0.01	≤ 0.001
PIM (ref. no use) ^c	0.01	− 0.03 to 0.06	0.533	0.01	− 0.01 to 0.03	0.535	− 0.02	− 0.10 to 0.05	0.533
Antipsychotics (ref. no use) ^b	− 0.14	− 0.21 to − 0.08	≤ 0.001	− 0.06	− 0.10 to − 0.03	≤ 0.001	0.21	0.12 to 0.31	≤ 0.001
Sedative and hypnotics (ref. no use) ^b	− 0.01	− 0.11 to 0.08	0.742	− 0.01	− 0.05 to 0.03	0.742	0.02	− 0.11 to 0.16	0.742
Antidepressants (ref. no use) ^b	− 0.02	− 0.07 to 0.03	0.484	− 0.01	− 0.03 to 0.01	0.485	0.02	− 0.05 to 0.11	0.484
Antidementia drug treatment (ref. no use) ^b	− 0.10	− 0.14 to − 0.05	≤ 0.001	− 0.04	− 0.07 to − 0.02	≤ 0.001	0.14	0.08 to 0.21	≤ 0.001
Number GP contacts ^c	± 0.00	− 0.01 to 0.01	0.744	± 0.00	− 0.01 to 0.01	0.744	± 0.00	− 0.01 to 0.01	0.744
Specialist contacts (ref. no use) ^b	0.03	− 0.01 to 0.08	0.105	0.01	− 0.01 to 0.03	0.061	− 0.05	− 0.12 to 0.01	0.088
Number hospital contacts ^b	± 0.00	− 0.01 to 0.01	0.372	± 0.00	− 0.01 to 0.01	0.379	± 0.00	− 0.01 to 0.01	0.373

Table 3 continued

<i>N</i> = 737	Early-stage dementia (17.8%)			Mild dementia (43.4%)			Moderate to severe dementia (38.8%)		
	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value	AME	95% CI	<i>p</i> value
Therapies contacts (ref. no use) ^b	0.04	0.00 to 0.08	0.030	0.02	0.00 to 0.04	0.047	– 0.06	– 0.12 to 0.01	0.033
Nursing contacts (ref. no use) ^b	0.01	– 0.03 to 0.06	0.545	0.01	– 0.01 to 0.02	0.522	– 0.02	– 0.08 to 0.04	0.538
Care level ^{a,b}									
1 (ref. no assignment)	– 0.02	– 0.14 to 0.08	0.610	– 0.01	– 0.04 to 0.02	0.692	0.03	– 0.11 to 0.18	0.628
2 (ref. no assignment)	– 0.09	– 0.14 to – 0.03	≤ 0.001	– 0.04	– 0.07 to – 0.01	0.005	0.13	0.05 to 0.21	≤ 0.001
3 (ref. no assignment)	– 0.09	– 0.16 to – 0.03	0.004	– 0.05	– 0.09 to – 0.01	0.033	0.14	0.03 to 0.25	0.008
4 or higher (ref. no assignment)	– 0.16	– 0.23 to – 0.10	≤ 0.001	– 0.17	– 0.29 to – 0.04	0.007	0.33	0.15 to 0.51	≤ 0.001

p values in bold indicate $p \leq 0.001$

AME average marginal effects, CI confidence interval, GP general practitioner, PIM potentially inappropriate medication

^aThe care level assigned by the long-term care insurance indicates the amount of care and support a patient receives owing to their functional impairment, ranging from 1 to 5, with 1 indicating some problems and 5 indicating extreme problems

^bAssumption based on literature: factor/variable is associated with higher severity

^cAssumption based on literature: factor/variable is associated with lower severity

for dementia received a formal diagnosis, leading to only 30% of patients being treated with adequate antidementia drugs [18, 24, 40]. In particular, the coded prevalence of mild cognitive impairment corresponded to less than 10% of its actual prevalence [41]. Current variables available in German claims data could be insufficient to classify early stages adequately. For this purpose, further research is needed—including advanced machine learning approaches applied to additional markers that also consider risk factors that occur years before dementia onset—to improve early-stage detection, predict transitions between dementia stages, and uncover latent trajectory patterns. Even though these approaches may appear promising, they also

depend on improved coding adherence for claims data [14–17]. Therefore, incentives are needed to improve physicians' coding practices, enabling access to optimal treatment and care and strengthening the quality of real-world data as a basis for decision-making.

The role of care levels as a severity marker was also evident, with PPV rising from 7.8% in early-stage to 59.6% in severe dementia. This stepwise increase highlights the utility of long-term care assignments in stratifying disease severity and corresponds to previous research demonstrating increased nursing care needs across different severity stages due to functional impairment [42–44]. The AME analysis confirmed that higher care levels significantly decreased

Table 4 Diagnostic performance metrics for dementia severity classification

<i>N</i> = 737	Early-stage dementia (17.8%)				Mild dementia (43.4%)				Moderate to severe dementia (38.8%)			
	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)
Antidementia drug only	15.3	72.0	79.7	10.5	22.5	71.7	54.7	37.9	34.3	79.6	65.6	51.6
Antipsychotic use only	3.8	87.3	80.8	6.1	8.1	86.6	55.1	31.7	17.8	93.1	64.1	62.2
Antidementia drug and antipsychotic use	2.3	95.4	81.9	9.7	1.3	93.5	55.2	12.9	8.4	98.5	62.9	77.4
Care level only ^a	11.5	70.6	78.7	7.8	19.7	68.8	52.8	32.6	40.2	82.7	68.6	59.6
Antidementia drug and care level ^a	3.1	91.4	81.4	7.1	4.1	89.7	54.9	23.2	13.6	96.2	63.7	69.6
Antipsychotic use and care level ^a	0.8	94.6	81.5	2.9	2.2	93.5	55.5	20.6	9.1	98.2	63.0	76.5

Table 4 continued

N = 737	Early-stage dementia (17.8%)			Mild dementia (43.4%)			Moderate to severe dementia (38.8%)		
	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)	Sensitivity (%)	Specificity (%)	NPV (%)	PPV (%)	PPV (%)
Antidementia drug and antipsychotic use and care level ^a	0.8	98.0	82.0	7.7	0.3	97.1	55.9	7.7	3.9
							99.6	62.0	84.6

NPV negative predictive value indicates the probability that an individual with a negative result does not belong to the assigned severity category, PPV positive predictive value indicates the probability that an individual with a positive result truly belongs to the assigned severity category

^aThe care level assigned by the long-term care insurance indicates the amount of care and support a patient receives owing to their functional impairment, ranging from 1 to 5, with 1 indicating some problems and 5 indicating extreme problems

early-stage classification probability (e.g., care level 4+, – 16%) while substantially increasing moderate to severe classification probabilities (+34%). These findings underscore the need to integrate care levels as a crucial predictor into prospective claims-based severity algorithms.

While our study identified strong predictors of dementia severity, several variables lost significance after applying the Bonferroni correction. Notably, diagnoses such as cancer were initially associated with dementia severity. However, they did not remain significant after correction of the *p* value, suggesting that cancer may co-occur with dementia, but the role as an independent predictor of severity is limited within the dataset used. The literature reveals contrasting evidence, including studies reporting an inverse association between cancer and dementia, indicating PwD may be less likely to be diagnosed with cancer and vice versa. At the same time, other findings suggest a positive association and highlight disparities in cancer care among patients with dementia [45, 46]. Thus, further research is needed.

Additionally, statistically significant unadjusted group differences occur for depression and diabetes. However, the recorded diagnoses increase from the early stages, peak in the mild stage, and decline again in the moderate to severe stages. The dementia progression could accompany decreased healthcare utilization and related diseases underdiagnoses. This tendency is in line with previous research. Eisele et al. [47] pointed out that the utilization of ambulatory medical care services increased in the year before and in the year after the incidence of dementia. Building upon this, Michalowsky et al. [40] demonstrated an association between dementia progression and reduced healthcare utilization. In the present analyses, the respective coefficients of healthcare utilization variables such as GP contacts, specialist visits, and therapies underscore these negative trends with dementia severity, even if these were not statistically significant. Nevertheless, prospective claims data analyses should examine this hypothesis to clarify the role of comorbidities in predicting dementia severity.

Overall, the findings have significant implications for both research and clinical practice.

Classifying dementia severity using real-world data can facilitate epidemiological surveillance, guide healthcare resource allocation, and support health economic evaluations. However, several limitations should be acknowledged. The sample used does not represent the German population, particularly regarding PwD. While it is assumed that up to two-thirds of patients are affected by Alzheimer's disease, the present sample covers only 46% of Alzheimer's cases in patients with a dementia-type specific diagnosis. However, 45% of the sample has an unspecific diagnosis, reflecting the clinical and coding practice of treating physicians [18]. A further limitation is the heterogeneity in diagnostic and prescribing practices across physicians, which may introduce variability unrelated to underlying dementia progression and could confound our identified associations. The role of antidementia drugs may be overestimated since memantine is officially recommended for later stages while acetylcholinesterase inhibitors target early disease [32]. In real-world practice, however, memantine is often used off-label in milder stages, especially when acetylcholinesterase inhibitors cause side effects or drug interactions [48]. Additionally, given known overuse and adverse events [49], antipsychotic prescriptions may reflect prescribing practices rather than underlying disease progression, and thus represent a potential confounder in our analysis. Moreover, the lower sensitivity for early-stage dementia suggests that claims-based approaches may miss a significant proportion of individuals in the initial disease phases. However, the present data does not include all the variables that a complete claims dataset contains, such as data for specific outpatient services or laboratory tests. Therefore, future studies should explore additional markers, such as cognitive screening data or healthcare service utilization patterns in longitudinal data, to improve early-stage detection and classification. As a result of data minimization, congruence between administrative claims and patient-reported data could not be assessed, as no individual variables were captured in both sources. Additionally, while specificity and PPV were high for severe dementia, these findings must be validated in external datasets to confirm their robustness and to examine the generalizability of these findings across diverse populations.

CONCLUSION

This study demonstrates that prescription patterns and care levels could be valuable indicators for distinguishing between early and advanced dementia stages in real-world data. While their combined specificity and PPV for moderate to severe dementia were high, particularly the sensitivity for early-stage classification remains a challenge. Moreover, accurate identification of dementia in administrative data is hampered by inadequate coding practices and underdiagnosis, with 23% of dementia cases not recorded and specific etiologies missing in 68% of records. Future efforts should aim to refine early detection models, explore complementary data sources to improve dementia severity stratification, and facilitate targeted access to necessary dementia treatments.

ACKNOWLEDGEMENTS

We thank the participants of the studies.

Author Contributions. All authors contributed to the study conception and design. Moritz Platen: data quality control, statistical analysis (conceptualization and design), manuscript (drafting and revision); Maresa Buchholz: statistical analysis (review and critique), manuscript (review and critique); Anika Rädke: manuscript (review and critique); Eva Gläser: manuscript (review and critique); Audrey Iskandar: manuscript (review and critique); Neeltje van den Berg: manuscript (review and critique); Wolfgang Hoffmann: manuscript (review and critique); Bernhard Michalowsky: Statistical analysis (conceptualization and design), manuscript (review and critique). All authors reviewed the manuscript.

Funding. No funding or sponsorship was received for the publication of this article. The Rapid Service Fee was funded by the authors.

Data Availability. The data used in the analysis is available upon request from the authors, in compliance with ethical and data protection regulations.

Declarations

Conflict of Interest. Moritz Platen, Maresa Buchholz, Anika Rädke, Eva Gläser, Audrey Iskandar, Neeltje van den Berg, Wolfgang Hoffmann and Bernhard Michalowsky have nothing to disclose.

Ethical Approval. This analysis utilized merged baseline data from three independent trials that were approved by the Ethical Committee of the Chamber of Physicians of Mecklenburg-Western Pomerania (registry numbers BB 20/11 for Delphi-MV, BB01/2019 for DCM:IMPact, and BB144/20 for InDePendent) and have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all study participants.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Schneeweiss S. Von Real-World-Daten zur Real-World-Evidenz: eine praktische Anleitung. Prävention und Gesundheitsförderung. 2023.
- Wicherski J, Schneider K, Zinserling J, Heß S, Haenisch B, Broich K. Real-world-Daten in der Arzneimittelregulation—aktuelle Entwicklungen und Ausblick. Prävention und Gesundheitsförderung. 2023.
- Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. *Pharmacoepidemiol Drug Saf.* 2020;29(10):1201–12.
- Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. *Clin Pharmacol Ther.* 2021;109(5):1212–8.
- Robinson L, Tang E, Taylor J-P. Dementia: timely diagnosis and early intervention. *BMJ.* 2015;350:h3029.
- Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA.* 2023;330(6):512–27.
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med.* 2023;388(1):9–21.
- Aye S, Johansson G, Hock C, et al. Point of view: challenges in implementation of new immunotherapies for Alzheimer's disease. *J Prev Alzheimers Dis.* 2025;12(1):100022.
- Wahlberg K, Winblad B, Cole A, et al. People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare. *J Intern Med.* 2024;295(3):281–91.
- Jönsson L, Wimo A, Handels R, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint. *Lancet Reg Health Eur.* 2023;29:100657.
- Grodstein F, Chang CH, Capuano AW, et al. Identification of dementia in recent Medicare claims data, compared with rigorous clinical assessments. *J Gerontol A Biol Sci Med Sci.* 2022;77(6):1272–8.
- Taylor DH Jr, Fillenbaum GG, Ezell ME. The accuracy of medicare claims data in identifying Alzheimer's disease. *J Clin Epidemiol.* 2002;55(9):929–37.
- Wilkinson T, Ly A, Schnier C, et al. Identifying dementia cases with routinely collected health data: a systematic review. *Alzheimers Dement.* 2018;14(8):1038–51.
- Anand P, Zhang Y, Ngan K, et al. Identifying dementia severity among people living with dementia using administrative claims data. *J Am Med Dir Assoc.* 2024;25(9):105129.

15. Nori VS, Hane CA, Martin DC, Kravetz AD, Sanghavi DM. Identifying incident dementia by applying machine learning to a very large administrative claims dataset. *PLoS ONE*. 2019;14(7):e0203246.
16. Park CM, Sison SDM, McCarthy EP, et al. Claims-based frailty index as a measure of dementia severity in medicare claims data. *J Gerontol A Biol Sci Med Sci*. 2023;78(11):2145–51.
17. Reinke C, Doblhammer G, Schmid M, Welchowski T. Dementia risk predictions from German claims data using methods of machine learning. *Alzheimers Dement*. 2023;19(2):477–86.
18. Eichler T, Thyrian JR, Hertel J, et al. Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial. *J Alzheimers Dis*. 2014;42(2):451–8.
19. Zhu CW, Ornstein KA, Cosentino S, Gu Y, Andrews H, Stern Y. Misidentification of dementia in medicare claims and related costs. *J Am Geriatr Soc*. 2019;67(2):269–76.
20. Niznik JD, Lund JL, Hanson LC, et al. A comparison of dementia diagnoses and cognitive function measures in Medicare claims and the Minimum Data Set. *J Am Geriatr Soc*. 2024;72(8):2381–90.
21. Koller D, Hua T, Bynum JP. Treatment patterns with antidementia drugs in the United States: Medicare cohort study. *J Am Geriatr Soc*. 2016;64(8):1540–8.
22. Schwarzkopf L, Menn P, Holle R. Discretionary decisions in claims data analyses and their effects—an explorative comparison using the example of a cost of illness study on dementia. *Gesundheitswesen*. 2012;74(8–9):e76–83.
23. Schubert I, Ihle P, Köster I. Internal confirmation of diagnoses in routine statutory health insurance data: concept with examples and case definitions. *Gesundheitswesen*. 2010;72(6):316–22.
24. Wucherer D, et al. Antidementia drug treatment in people screened positive for dementia in primary care. *J Alzheimers Dis*. 2015;44(3):1015–21.
25. Riedel O, Braitmaier M, Langner I. Dementia in health claims data: the influence of different case definitions on incidence and prevalence estimates. *Int J Methods Psychiatr Res*. 2023;32(2):e1947.
26. Schulze J, Glaeske G, Bussche H, et al. Prescribing of antipsychotic drugs in patients with dementia: a comparison with age-matched and sex-matched non-demented controls. *Pharmacoepidemiol Drug Saf*. 2013;22(12):1308–16.
27. Kleinke F, Michalowsky B, Rädke A, et al. Advanced nursing practice and interprofessional dementia care (InDePendent): study protocol for a multicenter, cluster-randomized, controlled, interventional trial. *Trials*. 2022;23(1):290.
28. Platen M, Hoffmann W, Rädke A, et al. Translation of collaborative dementia care management into different healthcare settings: study protocol for a multicenter implementation trial (DCM:IMPact). *J Alzheimers Dis Rep*. 2022;6(1):617–26.
29. Thyrian JR, Fiß T, Dreier A, et al. Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial. *Trials*. 2012;13:56.
30. Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. *Int J Geriatr Psychiatry*. 2004;19(2):136–43.
31. Kessler J, Markowitsch H, Denzler P. Mini-Mental-Status-Test (MMST) [German Version]. 1 ed. 1990, Göttingen: Beltz Test GmbH.
32. Deutsche Gesellschaft für Psychiatrie Psychotherapie und Nervenheilkunde und Deutsche Gesellschaft für Neurologie, S3-Leitlinie Demenzen. 2017, Berlin: Springer.
33. Kohn N, Kalbe E, Georg H, Kessler J. Vergleich MMST und demtect: spezifität und sensitivität bei primär kognitiven störungen. *Aktuelle Neurologie*. 2007;34(S2):P672.
34. Seidl H, Bowles D, Bock JO, et al. FIMA—Fragebogen zur Erhebung von Gesundheitsleistungen im Alter: Entwicklung und Pilotstudie. *Gesundheitswesen*. 2015;77(01):46–52.
35. Teipel S, Akmatov M, Michalowsky B, Riedel-Heller S, Bohlken J, Holstiege J. Timing of risk factors, prodromal features, and comorbidities of dementia from a large health claims case-control study. *Alzheimers Res Ther*. 2025;17(1):22.
36. StataCorp., Stata Statistical Software: release 18. College Station: StataCorp LLC. 2023.
37. Bohlken J, Booker A, Kostev K. High prevalence of antipsychotic medication use in dementia patients in German Neuropsychiatric Practices. *Fortschr Neurol Psychiatr*. 2017;85(6):345–51.
38. Hessmann P, Dodel R, Baum E. Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany. *Int J Psychiatry Clin Pract*. 2018;22(3):232–9.

-
39. Rogowska M, Thornton B, Creese B. Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011–2022 update. *Drugs Aging*. 2023;40(1):21–32.
40. Michalowsky B, Flessa S, Eichler T. Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial. *Eur J Health Econ*. 2018;19(1):87–102.
41. Bohlken J, Kostev K. Coded prevalence of mild cognitive impairment in general and neuropsychiatrists practices in germany between 2007 and 2017. *J Alzheimers Dis*. 2019;67(4):1313–8.
42. Giebel CM, Sutcliffe C, Challis D. Activities of daily living and quality of life across different stages of dementia: a UK study. *Aging Ment Health*. 2015;19(1):63–71.
43. Keck A, Pendergrass A, Gräbel E. [Need for care in old age: characterization of informal caregivers and the care situation with regard to care levels in home care]. *Gesundheitswesen*. 2024;86(01):S3–s12.
44. Platen M, Hoffmann W, Michalowsky B. Comparing different implementation strategies for collaborative dementia care management in terms of patients' characteristics, unmet needs, and the impact on quality of life and costs in Germany. *Pharmacoecoon Open*. 2025;9(2):271–82.
45. Hopkinson JB, Milton R, King A, Edwards D. People with dementia: what is known about their experience of cancer treatment and cancer treatment outcomes? A systematic review. *Psychooncology*. 2016;25(10):1137–46.
46. van der Willik KD, Schagen SB, Ikram MA. Cancer and dementia: two sides of the same coin? *Eur J Clin Invest*. 2018;48(11):e13019.
47. Eisele M, van den Bussche H, Koller D, et al. Utilization patterns of ambulatory medical care before and after the diagnosis of dementia in Germany—results of a case-control study. *Dement Geriatr Cogn Disord*. 2010;29(6):475–83.
48. DiBello JR, Lu Y, Swartz J, et al. Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD). *BMC Neurol*. 2023;23(1):400.
49. Platen M, Flessa S, Teipel S, et al. Impact of low-value medications on quality of life, hospitalization and costs—a longitudinal analysis of patients living with dementia. *Alzheimers Dement*. 2023;19(10):4520–31.
-